Synthelabo

Other

Salomon Z Langer

Icilio A Cavero

Michael A Kapin

Mireille Sevrin

Billie M York

Dennis C Bigg

Jonathan Reid Frost

Louis DeSantis, Jr

Alexander E Wick

Claude C Morel

Bernard Gaudilliere

Louis M Desantis, Jr

Jean Rousseau

Regis Dupont

Jean Bertin

Bernard Scatton

Johannes Schoemaker

Peter Hicks

Allan G Roach

Jean-Louis Cazor

The use of polyamine site antagonists in treating ischemic disorders of the retina and optic nerve head are disclosed. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Treatment of ischemic disorders of the retina and optic nerve head

Polyamine antagonists are found to be effective in preventing or reducing visual field loss associated with glaucoma. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Use of polyamine antagonists for the treatment of glaucoma

Ifenprodil and its analogues are useful for the treatment of psychoses such as schizophrenia.

Method of treatment of psychotic disorders

Pharmaceutical compositions containing, by way of active substance, a combination of an alpha-blocker and a calcium antagonist. The composition is useful in treating cardiovascular disorders, especially hypertension.

Pharmaceutical compositions

2-(4,5-Dihydro-1H-imidazol-2-yl)-1,2,4,5-tetrahydropyrrolo[3,2,1-hi]indole derivatives and their pharmaceutically acceptable salts are useful an antidiabetic agents.

2-(4,5-dihydro-1H-imidazol-2-yl)-1,2,4,5-tetrahydropyrrolo[3,2,1

Pharmaceutical composition containing both diltiazem and lysine acetylsalicylate exhibits enhanced platelet aggregation inhibitory properties.

Pharmaceutical compositions based on diltiazem and lysine

A method of treatment of obesity which comprises administering to a subject liable thereto or suffering therefrom an effective dose of 4-(2-naphthylmethoxy)piperidine.

Pharmaceutical composition for treatment of obesity

2-dipropylamino-5 or -7-formylamino-6-hydroxy-1,2,3-4-tetrahydronaphthalene and their pharmaceutically acceptable salts are useful as antiglaucoma agents.

1,2,3,4-tetrahydronaphthalene derivatives used as antiglaucoma agents

2-Dipropylamino-5 or -7-formylamino-6-hydroxy-1,2,3-4-tetrahydronaphthalene and their pharmaceutically acceptable salts are useful as anti-ulcer agents.

Anti-ulcer agents

A method is provided of treating glaucoma in a patient which comprises administering, preferably as eye drops, an effective amount of the compound ##STR1## which is preferably in the form of its hydrochloride. The compound is administered preferably in the form of a sterile pharmacologically acceptable solution which contains from 0.1 to 5, and more preferably 0.1 to 2.0, percent by weight of said compound. The patient preferably obtains the anti-glaucoma agent in the form of a kit which comprises the sterile pharmacologically acceptable solution and an eyedropper for dispensing said sterile pharmacologically acceptable solution to the affected eyes of a patient suffering from glaucoma.

Method of lowering intraocular pressure using phenylimino-imidazoles

A method is provided for lowering the gastric acidity in the patient by administering to said patient an effective amount of 5-(2-dimethylamino-ethyl)-cis-2-(4-methoxy-phenyl)-4-oxo-2,3-dihydro-5H-1, 5-benzothiazepin-3-yl acetate or a pharmaceutically acceptable salt thereof to reduce said gastric acidity.

Growing community of inventors

Paris, France

Salomon Z Langer